JP4927733B2 - 置換ヒダントイン - Google Patents

置換ヒダントイン Download PDF

Info

Publication number
JP4927733B2
JP4927733B2 JP2007526351A JP2007526351A JP4927733B2 JP 4927733 B2 JP4927733 B2 JP 4927733B2 JP 2007526351 A JP2007526351 A JP 2007526351A JP 2007526351 A JP2007526351 A JP 2007526351A JP 4927733 B2 JP4927733 B2 JP 4927733B2
Authority
JP
Japan
Prior art keywords
phenyl
dioxo
imidazolidin
thiazol
butyramide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007526351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509950A5 (enExample
JP2008509950A (ja
Inventor
チュ，シン−ジェ
フォトゥーイ，ナデ
ジョン シルベスター ハビー，ニコラス
コン，ノーマン
アポストル マクダーモット，リー
アンソニー モリターニ，ジョン
チャン，チューミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2008509950A publication Critical patent/JP2008509950A/ja
Publication of JP2008509950A5 publication Critical patent/JP2008509950A5/ja
Application granted granted Critical
Publication of JP4927733B2 publication Critical patent/JP4927733B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2007526351A 2004-08-17 2005-08-09 置換ヒダントイン Expired - Fee Related JP4927733B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60217504P 2004-08-17 2004-08-17
US60/602,175 2004-08-17
US68299705P 2005-05-20 2005-05-20
US60/682,997 2005-05-20
PCT/EP2005/008633 WO2006018188A2 (en) 2004-08-17 2005-08-09 Substituted hydantoins

Publications (3)

Publication Number Publication Date
JP2008509950A JP2008509950A (ja) 2008-04-03
JP2008509950A5 JP2008509950A5 (enExample) 2012-01-05
JP4927733B2 true JP4927733B2 (ja) 2012-05-09

Family

ID=35589619

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007526351A Expired - Fee Related JP4927733B2 (ja) 2004-08-17 2005-08-09 置換ヒダントイン

Country Status (16)

Country Link
US (1) US7427635B2 (enExample)
EP (1) EP1781649B1 (enExample)
JP (1) JP4927733B2 (enExample)
KR (2) KR100889721B1 (enExample)
AR (1) AR050297A1 (enExample)
AT (1) ATE404556T1 (enExample)
AU (1) AU2005274390B2 (enExample)
BR (1) BRPI0514515A (enExample)
CA (1) CA2576599A1 (enExample)
DE (1) DE602005008986D1 (enExample)
ES (1) ES2313389T3 (enExample)
MX (1) MX2007001846A (enExample)
PL (1) PL1781649T3 (enExample)
RU (1) RU2383542C2 (enExample)
TW (1) TW200621764A (enExample)
WO (1) WO2006018188A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
CA2686756A1 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
ES2383927T3 (es) * 2007-08-16 2012-06-27 F. Hoffmann-La Roche Ag Hidantoínas sustituidas
CA2707650A1 (en) * 2007-12-20 2009-07-02 F. Hoffmann-La Roche Ag Substituted hydantoins as mek kinase inhibitors
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
DK2303021T3 (en) * 2008-06-16 2019-04-08 Univ Tennessee Res Found RELATIONSHIPS FOR TREATING CANCER
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
WO2011000945A2 (en) * 2009-07-03 2011-01-06 Nensius Research A/S Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
ES2674682T3 (es) 2010-02-25 2018-07-03 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
MX377405B (es) 2010-03-01 2025-03-07 Gtx Inc Compuestos para el tratamiento de cáncer.
WO2011112678A1 (en) 2010-03-09 2011-09-15 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
CN102971314B (zh) 2010-04-28 2016-03-23 拜耳知识产权有限责任公司 酮基杂芳基哌啶和酮基杂芳基哌嗪衍生物作为杀菌剂
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
UA125427C2 (uk) * 2018-09-17 2022-03-02 Юнґдзин Фарм. Ко., Лтд. Похідні тіазолу і їх фармацевтично прийнятні солі
KR20210116325A (ko) * 2020-03-13 2021-09-27 영진약품 주식회사 티아졸 유도체 또는 이의 약제학적으로 허용가능한 염을 포함하는 암의 예방 또는 치료용 약학 조성물
WO2021182914A1 (ko) * 2020-03-13 2021-09-16 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
KR20210146144A (ko) 2020-05-26 2021-12-03 엘지전자 주식회사 카트부

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
JP3842131B2 (ja) * 2000-05-03 2006-11-08 エフ．ホフマン−ラ ロシュ アーゲー ヒダントイン含有グルコキナーゼ活性化物質
ATE345341T1 (de) * 2001-07-19 2006-12-15 Pfizer Italia Srl Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel

Also Published As

Publication number Publication date
KR20090006885A (ko) 2009-01-15
WO2006018188A2 (en) 2006-02-23
ATE404556T1 (de) 2008-08-15
EP1781649A2 (en) 2007-05-09
DE602005008986D1 (de) 2008-09-25
RU2383542C2 (ru) 2010-03-10
WO2006018188A3 (en) 2006-05-18
AU2005274390B2 (en) 2012-01-19
JP2008509950A (ja) 2008-04-03
US7427635B2 (en) 2008-09-23
EP1781649B1 (en) 2008-08-13
MX2007001846A (es) 2007-03-28
KR100889721B1 (ko) 2009-03-23
AR050297A1 (es) 2006-10-11
US20060041146A1 (en) 2006-02-23
BRPI0514515A (pt) 2008-06-10
CA2576599A1 (en) 2006-02-23
RU2007109651A (ru) 2008-09-27
PL1781649T3 (pl) 2009-01-30
TW200621764A (en) 2006-07-01
ES2313389T3 (es) 2009-03-01
AU2005274390A1 (en) 2006-02-23
KR20070034635A (ko) 2007-03-28

Similar Documents

Publication Publication Date Title
JP4927733B2 (ja) 置換ヒダントイン
KR101060981B1 (ko) 히단토인 기재 키나아제 억제제
JP5583694B2 (ja) Ｃｂ２受容体を調節するピロリジン化合物
JP5781611B2 (ja) Ｌｒｒｋ２キナーゼ阻害剤としての２−（ベンジルオキシ）ベンズアミド類
KR100869681B1 (ko) 암 치료를 위한 치환된 히단토인
AU2009249874A1 (en) Phenyl and benzodioxinyl substituted indazoles derivatives
US20200223837A1 (en) Benzofuran amides and heteroaromatic analogues thereof for use in therapy
US20200216435A1 (en) Bicyclic heteroaromatic amide compounds for use in therapy
JP2010536723A (ja) 置換ヒダントイン
CN101896469A (zh) 作为mek激酶抑制剂的取代的乙内酰脲类化合物
CN101006085A (zh) 取代的乙内酰脲类
CN101389609B (zh) 基于乙内酰脲的激酶抑制剂
AU2015340584B2 (en) Benzylhydroxyde derivatives, preparation thereof and therapeutic use thereof
JP2020523391A (ja) 治療への使用のためのベンゾフラン尿素またはカルバメートおよびそれらの複素芳香族アナログ
HK1162504A (en) Novel bicyclic heterocyclic compound

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100819

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100826

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110420

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110713

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110721

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20111111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120110

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120209

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150217

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees